Who
Christopher Twitty
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Skye Bioscience; Director, ZyVersa Therapeutics.
In numbers
- Trades disclosed
- 27
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 6 Jan 2022
- Last trade
- 31 Mar 2026
- Last filed
- 2 Apr 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,004 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —150,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —12,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —17,004 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,004 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —17,004 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —75,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,100 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —7,100 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —200,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —200,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —150,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —150,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —12,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code D | —75,000 | filing |
| 31 Mar 2026filed 2 Apr 2026 | SKYE Skye Bioscienceoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,100 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.